Every 424B that Relay Therapeutics, Inc. (RLAY) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow RLAY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RLAY filings page.
Relay Therapeutics, Inc. is offering up to $212,978,049 of common stock from time to time under an amended sales agreement with TD Securities (USA) LLC (TD Cowen) as an at-the-market program on The Nasdaq Global Market.
The company previously sold 16,006,569 shares under the original agreement, leaving about $87,021,951 of capacity there. As of June 30, 2026, 218,531,200 shares were outstanding. An illustrative sale of 11,310,570 shares at $18.83 per share would raise $213.0 million and increase net tangible book value from $3.89 to $4.61 per share, implying dilution of $14.22 per share for new investors at that price.
Relay plans to use any proceeds, together with existing cash, to fund research and clinical development of pipeline candidates, working capital, capital expenditures and general corporate purposes. TD Cowen will earn up to a 3.0% commission on gross proceeds and may be deemed an underwriter, with customary indemnification. The company warns that investing involves a high degree of risk and highlights potential dilution and stock price impact from future equity issuances.
Relay Therapeutics is offering 22,916,667 shares of common stock at $12.00 per share. The prospectus supplement dated May 20, 2026 states estimated net proceeds of approximately $258.0 million (about $296.8 million if the underwriters exercise their 30-day option in full for an additional 3,437,500 shares). The offering assumes 189,209,453 shares outstanding as of March 31, 2026. Net tangible book value per share would be $4.24 after the offering, producing immediate dilution of $7.76 per new share. Proceeds are planned to fund research and clinical development, working capital, capital expenditures and general corporate purposes.
Relay Therapeutics is offering $175,000,000 of common stock. The preliminary prospectus supplement dated May 19, 2026, states the company is offering shares of its common stock for aggregate proceeds of $175,000,000, with underwriters holding a 30-day option to purchase up to an additional $26,250,000 of shares.
All information about shares outstanding is based on 189,209,453 shares outstanding as of March 31, 2026. The prospectus supplement cites intended use of net proceeds to fund research and clinical development, working capital, capital expenditures and other general corporate purposes.